Celltrion's SteQeyma Receives Positive EU Recommendation for Expanded Pediatric Indications

Celltrion's biosimilar drug SteQeyma (ustekinumab) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for expanded indications to include pediatric Crohn's disease and pediatric ulcerative colitis. If approved by the European Commission, this will make SteQeyma available for treating inflammatory bowel diseases in children aged 2 and older, enhancing treatment options for young patients.